不明原因慢性肾脏病成人全国队列的基因检测
荷兰多中心前瞻性队列研究纳入340例50岁前起病的不明原因CKD成人,采用大规模平行测序多基因panel检测,17%检出诊断性变异,最常见为NPHP1、COL4A3/COL4A4/COL4A5和PAX2;73%患者因此产生至少一项临床决策改变。荷兰肾内科医生调查显示主要障碍为遗传知识不足、检测选择困难和时间缺乏。
要点
- 50岁前起病的不明原因CKD成人中,MPS多基因panel诊断率为17%。
- 检出变异以NPHP1、COL4A3/COL4A4/COL4A5和PAX2最常见。
- 基因诊断使73%患者产生至少一项临床决策改变。
核心结论
- MPS多基因panel在不明原因CKD成人中诊断率为17%,支持其用于50岁前起病者的诊断流程。
研究设计与样本
- 前瞻性队列研究,纳入荷兰11家学术与非学术医院中50岁前起病、eGFR<60 ml/min/1.73 m2且无明确临床诊断的不明原因CKD成人,行MPS多基因panel检测。
- 对检出(可能)致病性变异的患者,验证该变异是否可能解释临床表型。
- 向荷兰全体肾内科医生及住院医师发放全国在线调查,评估基因panel检测的实施障碍。
主要发现
- 340例参与者中59例(17%)检出诊断性变异。
- 最常见的诊断性变异所在基因为NPHP1(13例)、COL4A3(12例)、COL4A4(5例)、COL4A5(6例)和PAX2(5例)。
- 基因诊断使73%的患者产生至少一项临床决策改变。
- 71名荷兰肾内科医生报告的主要障碍包括遗传知识不足(53%)、检测选择困难(51%)和时间缺乏(43%)。
临床怎么用
- 对50岁前起病的不明原因CKD成人,可考虑MPS多基因panel检测以明确遗传诊断。
- 遗传诊断可影响临床决策,应关注检测后的临床管理调整。
- 需加强肾内科医生的遗传学教育并优化检测选择流程以促进实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) remains unexplained in at least 20% of patients. Massively parallel sequencing (MPS) can be a valuable diagnostic tool in patients with unexplained CKD, but prospective data from routine clinical practice are limited. We aimed to determine the diagnostic yield and relevance of MPS-based gene panel testing in patients with unexplained CKD in a real-world context. We additionally examined barriers to implementation of genetic testing. METHODS: In this prospective cohort study, we recruited patients with unexplained CKD (estimated glomerular filtration rate <60 ml/min/1.73 m2 without underlying clinical diagnosis) with onset at <50 years of age who underwent MPS-based multigene panel testing from 11 academic and non-academic hospitals across the Netherlands. In patients with a (likely) pathogenic variant, we verified that the variant likely explained the clinical phenotype. A nationwide online survey was sent to all Dutch nephrologists and residents to investigate potential barriers for gene panel testing. RESULTS: A diagnostic variant was identified in 59/340 participants (17%). Most common diagnostic variants were in NPHP1 (13 patients), COL4A3 (12 patients), COL4A4 (5 patients), COL4A5 (6 patients) and PAX2 (5 patients). A genetic diagnosis led to at least one clinical consequence in 73% of patients. Main barriers reported by Dutch nephrologists (N = 71) included genetic illiteracy (53%), difficulties with test selection (51%) and a lack of time (43%). CONCLUSIONS: MPS-based multigene panel testing yielded a genetic diagnosis in 17% of patients with unexplained CKD. Our findings support the relevance of MPS in the diagnostic workup of adults with unexplained CKD with onset at <50 years of age. Additionally, our results underline the need to improve genetic education among nephrologists to better the implementation of MPS-based diagnostic testing in clinical practice.
引用
- de Haan A, Eijgelsheim M, Vogt L, et al. Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin. Nephrol Dial Transplant. 2025. PMID: 39562282. doi:10.1093/ndt/gfae270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。